StockData
TransMedics Group, Inc. logo

TransMedics Group, Inc. (TMDX) income statement

TMDXNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/3029% below fair value
$96.43+2.52 (+2.68%)

Close on Nov 18, 2026Market cap $3.34BP/E 25.0Yield 0.00%

TransMedics Group, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
58.7%
Operating margin
12.2%
Net margin
22.7%
Return on equity, FY2025
54.2%

Financial strength

Current ratio
6.62
Debt to equity
–
Debt to assets
–
Cash to current liabilities
480.9%

Valuation

P/E ratio
25.0
Price to sales
5.00
Price to book
6.45
Dividend yield
0.00%

See a number that looks wrong?